Drug
Apf530
Apf530: highest development phase Phase 3, developed by Heron Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Heron Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| APF530 NCT02106494 | Phase 3 | Chemotherapy-induced Nausea and Vomiting |
| APF530 NCT00343460 | Phase 3 | Nausea and Vomiting |
Latest
No recent events.
Follow Apf530 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.